Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 481-488 , August 2008

Clinical Significance of Troponin I Efflux and Troponin Autoantibodies in Patients With Dilated Cardiomyopathy

  • Kati H. Miettinen, MSc

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • Corresponding Author InformationReprint requests: Kati Miettinen, MSC, Kuopio University Hospital, Department of Internal Medicine, P.O. Box 1777, FI-70211 Kuopio, Finland.
    • ,
  • Susann Eriksson, PhD

      Affiliations

    • University of Turku, Turku, Finland
    • ,
  • Jarkko Magga, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • ,
  • Petri Tuomainen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • ,
  • Johanna Kuusisto, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • ,
  • Esko J. Vanninen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • ,
  • Anu Turpeinen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • ,
  • Kari R. Punnonen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • ,
  • Kim Pettersson, PhD

      Affiliations

    • University of Turku, Turku, Finland
    • ,
  • Keijo J. Peuhkurinen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland

Received 4 June 2007 ,Revised 15 February 2008 ,Accepted 21 February 2008.

References 

  1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–842
  2. Richard P, Villard E, Charron P, Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol. 2006;48:A79–A89
  3. Noutsias M, Pauschinger M, Poller WC, Schultheiss HP, Kuhl U. Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit. 2003;3:127–135
  4. Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S. BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005;30:535–544
  5. Okazaki T, Honjo T. Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends Mol Med. 2005;11:322–326
  6. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:C3–C8
  7. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003;60:5–10
  8. Bohner J, von Pape KW, Hannes W, Stegmann T. False-negative immunoassay results for cardiac troponin I probably due to circulating troponin I autoantibodies. [Letter] Clin Chem. 1996;42:2046
  9. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4:411–417
  10. Mobini R, Maschke H, Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. Autoimmun Rev. 2004;3:277–284
  11. Shmilovich H, Danon A, Binah O, Roth A, Chen G, Wexler D, et al. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. Int J Cardiol. 2007;117:198–203
  12. Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152:697–704
  13. Sato Y, Kataoka K, Matsumori A, Sasayama S, Yamada T, Ito H, et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart. 1997;78:505–508
  14. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Osada H, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103:369–374
  15. Horwich TB, Patel J, MacLellan R, Funarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–838
  16. Stanton EB, Hansen MS, Sole MJ, Gawad Y, Packer M, Pitt B, et al. PROFILE investigators. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Can J Cardiol. 2005;21:39–43
  17. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477–1483
  18. Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Öttl R, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. 2006;114:1693–1702
  19. Eriksson S, Junikka M, Laitinen P, Majamaa-Voltti K, Alfthan H, Pettersson K. Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. Clin Chem. 2003;49:1095–1104
  20. Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem. 2005;51:839–847
  21. Eriksson S, Ilva T, Becker C, Lund J, Porela P, Pulkki K, et al. Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin Chem. 2005;51:848–855
  22. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). Am J Cardiol. 1992;69:1458–1466
  23. Whipp BJ, Davis JA, Torres F, Wasserman K. A test to determine parameters of aerobic function during exercise. J Appl Physiol. 1981;50:217–221
  24. Sipola P, Vanninen E, Aronen HJ, Lauerma K, Simula S, Jääskeläinen P, et al. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogeneous subjects with hypertrophic cardiomyopathy. J Nucl Med. 2003;44:487–493
  25. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50:1576–1588
  26. Kontos MC, Shah R, Fritz LM, Anderson FP, Tatum JL, Ornato JP, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol. 2004;43:958–965
  27. Waxman DA, Hecht S, Schappert J, Husk G. A model for troponin I as a quantitative predictor of in-hospital mortality. J Am Coll Cardiol. 2006;48:1755–1762
  28. Komajda M, Jais JP, Reeves F, Goldfarb B, Bouhour JB, Juillieres Y, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J. 1990;11:824–831
  29. van den Broek SA, van Veldhuisen DJ, de Graeff PA, Landsman ML, Hillege H, Lie KI. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;70:359–363
  30. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564–1575
  31. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis. 2002;44:293–321
  32. Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol. 2006;33:1269–1274
  33. Rutschow S, Li J, Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res. 2006;69:646–656
  34. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78:1192–1199

 Conflict of interest statement: Susann Eriksson has a conflict of interest due to recent employment by Innotrac Diagnostics Oy. For the other authors, no conflict of interest exists.

 This study was supported by the Finnish Foundation for Cardiovascular Research, Aarne Koskelo Foundation, Ida Montin Foundation, and The Maud Kuistila Memorial Foundation.

PII: S1071-9164(08)00076-6

doi: 10.1016/j.cardfail.2008.02.009

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 481-488 , August 2008

Article Tools

* Image Usage & Resolution